Observational studyInternational journal of chronic obstructive pulmonary disease2017
The contribution of symptoms and comorbidities to the economic impact of COPD: an analysis of the German COSYCONET cohort.
Observational study in International journal of chronic obstructive pulmonary disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01245933 (Impact of Systemic Manifestations/Comorbidities on Clinical State, Prognosis and Utilisation of Health Care Resources in Patients With COPD), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of Systemic Manifestations/Comorbidities on Clinical State, Prognosis and Utilisation of Health Care Resources in Patients With COPD
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparative analysis of burden of topmost disorders requiring rehabilitation services: a systematic review and meta-analysis.Journal of translational medicine · 2025Pooled it
- Management of Cough in Patients with Chronic Obstructive Pulmonary Disease: Results of the Multicenter Randomized Placebo-Controlled Clinical Trial.International journal of chronic obstructive pulmonary diseaseTrial
- Tailored Exercise Prescription for People with COPD and Clinically Relevant Comorbidities: A Consensus Statement of the EXPERT Working Group and Experts in Pulmonary Rehabilitation.Sports medicine (Auckland, N.Z.) · 2026Review
- Epidemiological characteristics of respiratory diseases in emergency department patients from different ethnic groups in the Atushi region, Xinjiang.Frontiers in medicine · 2025Article
- Economic Burden of Chronic Obstructive Pulmonary Disease: A Systematic Review.Tuberculosis and respiratory diseases · 2024Article
- The overlap of chronic obstructive pulmonary disease and obstructive sleep apnea in hospitalizations for acute exacerbation of chronic obstructive pulmonary disease.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2024Article
- Nonpharmacological management of psychological distress in people with COPD.European respiratory review : an official journal of the European Respiratory Society · 2023Review
- [What have we learned from the German COPD cohort COSYCONET and where do we go from here?]Pneumologie (Stuttgart, Germany) · 2023Article
- Impact of Positive Airway Pressure Therapy Adherence on Outcomes in Patients with Obstructive Sleep Apnea and Chronic Obstructive Pulmonary Disease.American journal of respiratory and critical care medicine · 2022Observational
- Age- and gender-based comorbidity categories in general practitioner and pulmonology patients with COPD.NPJ primary care respiratory medicine · 2022Article
- Basic Determinants of Disease Knowledge in COPD Patients: Results from COSYCONET.Patient preference and adherence · 2022Article
- Cost analysis of chronic obstructive pulmonary disease (COPD): a systematic review.Health economics review · 2021Review
- Chronic obstructive pulmonary disease (COPD) in Spain and the different aspects of its social impact: a multidisciplinary opinion document.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2020Article
- Direct and indirect costs of COPD progression and its comorbidities in a structured disease management program: results from the LQ-DMP study.Respiratory research · 2019Article
- Impact of Disease-Specific Fears on Pulmonary Rehabilitation Trajectories in Patients with COPD.Journal of clinical medicine · 2019Article
- Impact of cough and mucus on COPD patients: primary insights from an exploratory study with an Online Patient Community.International journal of chronic obstructive pulmonary disease · 2019Article
- Determinants of healthcare utilization and costs in COPD patients: first longitudinal results from the German COPD cohort COSYCONET.International journal of chronic obstructive pulmonary disease · 2019Observational
- Associations of Polymorphism of rs9944155, rs1051052, and rs1243166 Locus Allele in Alpha-1-antitrypsin with Chronic Obstructive Pulmonary Disease in Uygur Population of Kashgar Region.Chinese medical journal · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although patients with COPD often have various comorbidities and symptoms, limited data are available on the contribution of these aspects to health care costs. This study analyzes the association of frequent comorbidities and common symptoms with the annual direct and indirect costs of patients with COPD. Methods: Self-reported information on 33 potential comorbidities and symptoms (dyspnea, cough, and sputum) of 2,139 participants from the baseline examination of the German COPD cohort COSYCONET was used. Direct and indirect costs were calculated based on self-reported health care utilization, work absence, and retirement. The association of comorbidities, symptoms, and COPD stage with annual direct/indirect costs was assessed by generalized linear regression models. Additional models analyzed possible interactions between COPD stage, the number of comorbidities, and dyspnea. Results: Unadjusted mean annual direct costs were €7,263 per patient. Other than COPD stage, a high level of dyspnea showed the strongest driving effect on direct costs (+33%). Among the comorbidities, osteoporosis (+38%), psychiatric disorders (+36%), heart disease (+25%), cancer (+24%), and sleep apnea (+21%) were associated with the largest increase in direct costs ( Conclusion: Detailed knowledge about comorbidities in COPD is useful not only for clinical purposes but also to identify relevant cost factors and their interactions and to establish a ranking of major cost drivers. This could help in focusing therapeutic efforts on both clinically and economically important comorbidities in COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.